Study guide

12.3 Acute Diabetic Emergencies (DKA & HHS)

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

12.3 Acute Diabetic Emergencies (DKA & HHS)

Key Takeaways Explain This Topic AI

Diabetic ketoacidosis (DKA) is diagnosed by the biochemical triad: blood glucose >11.0 mmol/L (or known DM), capillary/venous beta-hydroxybutyrate ≥3.0 mmol/L (or urine ketones ≥2+), and venous bicarbonate <15.0 mmol/L and/or venous pH <7.30.

Euglycaemic DKA occurs predominantly in patients treated with SGLT2 inhibitors due to glycosuria-induced low insulin secretion and uninhibited glucagon release; management requires concurrent 10% dextrose with fixed-rate insulin from the outset.

First-line DKA resuscitation (JBDS guidelines) mandates 0.9% sodium chloride, a fixed-rate IV insulin infusion (FRIII) at 0.1 units/kg/h without an initial IV bolus, continued long-acting subcutaneous basal insulin, and KCl replacement once serum potassium drops below 5.5 mmol/L.

Hyperosmolar hyperglycaemic state (HHS) features severe hypovolaemia, glucose ≥30.0 mmol/L, calculated effective osmolality >320 mOsm/kg, and absence of significant ketoacidosis; fluid replacement over 48-72 hours is primary, insulin is withheld initially unless ketonaemia or glucose plateau occurs, and prophylactic LMWH is mandatory.

In severe hypoglycaemia with impaired consciousness, first-line medical therapy is 100-150 mL 20% dextrose IV; in sulfonylurea-induced refractory hypoglycaemia, octreotide directly inhibits beta-cell insulin secretion.

Last updated: September 2026

Acute decompensated diabetic metabolic emergencies—diabetic ketoacidosis (DKA) and hyperosmolar hyperglycaemic state (HHS)—represent life-threatening medical crises with distinct pathophysiology, biochemical parameters, and resuscitation protocols. Mastery of the Joint British Diabetes Societies (JBDS) guidelines for fluid, insulin, and electrolyte titration is a cornerstone of the MRCP(UK) Part 1 examination.

  • 1. Diabetic Ketoacidosis (DKA): Pathophysiology & Diagnostic Criteria
  • Pathophysiological Cascade

DKA arises from absolute or relative insulin deficiency compounded by an exaggerated surge of counter-regulatory stress hormones (glucagon, catecholamines, cortisol, growth hormone):

Unchecked Lipolysis: Adipose tissue triglyceride lipolysis releases non-esterified free fatty acids (FFAs) into the portal circulation.

Hepatic Ketogenesis: In the liver, diminished malonyl-CoA levels relieve physiological inhibition of carnitine palmitoyltransferase-1 (CPT-1) . FFAs are actively transported into hepatic mitochondria, undergoing beta-oxidation into acetyl-CoA, which condenses into acetoacetate and beta-hydroxybutyrate .

Acid-Base Disturbance: Accumulation of organic ketoacids generates a severe high anion gap metabolic acidosis with compensatory respiratory alkalosis (Kussmaul breathing: rapid, deep respirations to blow off carbon dioxide).

Osmotic Diuresis & Dehydration: Hyperglycaemia exceeds the renal absorptive threshold, triggering osmotic diuresis with marked loss of water, sodium, potassium, phosphate, and magnesium (average adult water deficit: 5 – 7 litres 5\text{–}7\text{ litres} 5 – 7 litres or 100 mL/kg 100\text{ mL/kg} 100 mL/kg ).

JBDS Diagnostic Triad for DKA

Diagnosis requires the presence of all three components:

D (Diabetes / Hyperglycaemia): Blood glucose > 11.0 mmol/L > 11.0\text{ mmol/L} > 11.0 mmol/L OR previously known diabetes mellitus.

K (Ketonaemia): Capillary / venous blood beta-hydroxybutyrate ≥ 3.0 mmol/L \ge 3.0\text{ mmol/L} ≥ 3.0 mmol/L (or heavy ketonuria ≥ 2 + \ge 2+ ≥ 2 + on dipstick if blood ketone testing unavailable). Point-of-care blood ketone meters specifically measure beta-hydroxybutyrate, avoiding the latency and false-negative profile of urine test strips (which measure only acetoacetate via the nitroprusside reaction).

A (Acidosis): Venous blood gas bicarbonate < 15.0 mmol/L < 15.0\text{ mmol/L} < 15.0 mmol/L and/or venous pH < 7.30 \text{pH} < 7.30 pH < 7.30 .

Euglycaemic DKA (euDKA)

Euglycaemic DKA is characterized by significant ketoacidosis ( pH < 7.30 \text{pH} < 7.30 pH < 7.30 , HCO 3 − < 15 mmol/L \text{HCO}_3^- < 15\text{ mmol/L} HCO 3 − ​ < 15 mmol/L , blood ketones ≥ 3.0 mmol/L \ge 3.0\text{ mmol/L} ≥ 3.0 mmol/L ) in the presence of normal or near-normal blood glucose ( < 11.0 mmol/L < 11.0\text{ mmol/L} < 11.0 mmol/L ):

Etiological Triggers: SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin), pregnancy (enhanced GFR and fetal glucose utilization), prolonged fasting, low-carbohydrate ketogenic diets, severe chronic liver disease, alcohol abuse.

SGLT2i Mechanism: SGLT2 inhibition promotes massive renal glycosuria, lowering circulating plasma glucose. The lower glucose dampens endogenous pancreatic insulin secretion while directly stimulating pancreatic alpha-cells to secrete glucagon. The resulting high glucagon-to-insulin ratio stimulates uninhibited hepatic CPT-1 activity and rapid ketogenesis despite euglycaemia.

Management Rule: Manage identically to standard DKA, but start 10% dextrose concurrently with fixed-rate insulin from the outset to prevent catastrophic hypoglycaemia while clearing ketonaemia.

2. Joint British Diabetes Societies (JBDS) DKA Management Protocol

Resuscitation focuses on restoring intravascular volume, suppressing lipolysis/ketogenesis with fixed-rate insulin, replacing potassium, and monitoring metabolic clearance targets. DKA Resuscitation Algorithm (JBDS Guidelines):

[Fluid Protocol: 0.9% NaCl]

- 1st L over 1h → 2nd L over 2h (+KCl) → 3rd L over 2h (+KCl) → 4th L over 4h (+KCl) → 5th L over 4h (+KCl) → 6th L over 8h (+KCl)

- When blood glucose < 14.0 mmol/L → Add 10% Dextrose at 125 mL/h concurrently with 0.9% NaCl

  • [Insulin Protocol: Fixed-Rate IV Infusion (FRIII)]
  • 0.1 units/kg/h based on actual body weight (NO IV bolus!)
  • Continue regular subcutaneous basal insulin (glargine/degludec) at normal schedule
  • [Potassium Replacement Protocol]
  • K+ > 5.5 mmol/L → Nil KCl
  • K+ 3.5–5.5 mmol/L → Add 40 mmol KCl per litre of IV fluid
  • K+ < 3.5 mmol/L → STOP/DELAY insulin, give urgent IV KCl (40–60 mmol/h) until K+ > 3.5 mmol/L
  • Metabolic Clearance Targets & Monitoring

Check capillary glucose and capillary blood ketones hourly; venous blood gas (VBG), potassium, and sodium at 2, 4, 8, 12, and 24 hours.

Clearance Targets:

Reduction in blood ketones by ≥ 0.5 mmol/L/hour \ge 0.5\text{ mmol/L/hour} ≥ 0.5 mmol/L/hour .

Increase in venous bicarbonate by ≥ 3.0 mmol/L/hour \ge 3.0\text{ mmol/L/hour} ≥ 3.0 mmol/L/hour .

Reduction in blood glucose by ≥ 3.0 mmol/L/hour \ge 3.0\text{ mmol/L/hour} ≥ 3.0 mmol/L/hour .

If clearance targets are not met: check infusion pump and cannula patency; increase insulin infusion rate by 1.0 unit/hour 1.0\text{ unit/hour} 1.0 unit/hour increments until target rates of fall are established.

DKA Resolution & Subcutaneous Transition

Resolution Criteria (JBDS): Blood beta-hydroxybutyrate < 0.6 mmol/L < 0.6\text{ mmol/L} < 0.6 mmol/L , venous pH > 7.30 \text{pH} > 7.30 pH > 7.30 , venous bicarbonate ≥ 18.0 mmol/L \ge 18.0\text{ mmol/L} ≥ 18.0 mmol/L , and patient is alert and tolerating oral intake.

Transition Rule: Administer subcutaneous rapid-acting prandial insulin with a meal, and continue the IV insulin infusion for 30–60 minutes after the injection before stopping the infusion. Stopping the infusion prematurely without prior subcutaneous cover precipitates rebound ketoacidosis.

Life-Threatening Complications of DKA

Cerebral Oedema: Occurs predominantly in children and young adults (peak incidence 4–12 hours into resuscitation). Driven by rapid reduction in serum effective osmolality and excessive fluid administration. Features: headache, lethargy, bradycardia, hypertension (Cushing's triad), declining GCS. Treatment: immediate IV mannitol ( 0.5 – 1.0 g/kg 0.5\text{–}1.0\text{ g/kg} 0.5 – 1.0 g/kg over 20 min) or hypertonic 3% saline ( 2.5 – 5.0 mL/kg 2.5\text{–}5.0\text{ mL/kg} 2.5 – 5.0 mL/kg ) , elevate bed head to 30°, restrict fluids, urgent non-contrast CT head.

Hyperchloraemic Metabolic Acidosis: Non-anion gap metabolic acidosis that routinely appears late during resuscitation. Caused by preferential renal excretion of ketoacids while infused chloride from large volumes of 0.9 % 0.9\% 0.9% NaCl ( 154 mmol/L Cl − 154\text{ mmol/L } \text{Cl}^- 154 mmol/L Cl − ) is retained. Self-limiting; does not require insulin prolongation once ketonaemia has resolved.

  • 3. Hyperosmolar Hyperglycaemic State (HHS)
  • Pathophysiology

HHS occurs predominantly in elderly Type 2 diabetic patients. A small amount of residual endogenous insulin is present—sufficient to suppress adipose lipolysis and prevent ketogenesis (antilipolytic insulin concentration is ~1/10th that needed for glucose disposal), but inadequate to stimulate peripheral glucose uptake or suppress hepatic gluconeogenesis. Unchecked extreme hyperglycaemia causes profound osmotic diuresis, evolving insidiously over days to weeks.

JBDS Diagnostic Criteria for HHS

Severe Dehydration & Hypovolaemia: Profound volume deficit ( 100 – 220 mL/kg 100\text{–}220\text{ mL/kg} 100 – 220 mL/kg , average 8 – 12 litres 8\text{–}12\text{ litres} 8 – 12 litres in an adult).

Marked Hyperglycaemia: Blood glucose typically ≥ 30.0 mmol/L \ge 30.0\text{ mmol/L} ≥ 30.0 mmol/L .

Elevated Serum Effective Osmolality: Calculated effective osmolality > 320 mOsm/kg > 320\text{ mOsm/kg} > 320 mOsm/kg ( 2 × [ Na + ] + glucose 2 \times [\text{Na}^+] + \text{glucose} 2 × [ Na + ] + glucose ). Total osmolality including urea is not used for management decisions because urea freely permeates cell membranes.

Absence of Significant Ketoacidosis: Venous pH > 7.30 \text{pH} > 7.30 pH > 7.30 , venous bicarbonate > 15.0 mmol/L > 15.0\text{ mmol/L} > 15.0 mmol/L , and blood ketones < 3.0 mmol/L < 3.0\text{ mmol/L} < 3.0 mmol/L (mild ketonuria/ketonaemia may occur secondary to starvation).

HHS Management Principles

Primary Therapy is Fluid Resuscitation: 0.9 % 0.9\% 0.9% sodium chloride is the initial crystalloid. Rehydrate slowly, aiming to replace the total fluid deficit over 48 to 72 hours .

Target Osmolality Fall: Target a gradual fall in serum osmolality of 3.0 – 8.0 mOsm/kg/hour 3.0\text{–}8.0\text{ mOsm/kg/hour} 3.0 – 8.0 mOsm/kg/hour . Precipitous osmolality drops risk cerebral oedema or central pontine myelinolysis.

Sodium Dynamics: In severe hyperglycaemia, water shifts from intracellular to extracellular compartments, diluting measured serum sodium. As rehydration proceeds and glucose drops, measured sodium will naturally rise. If measured sodium fails to rise or drops while glucose falls, free water is being administered too rapidly. Only switch to 0.45 % 0.45\% 0.45% NaCl if osmolality is not declining despite adequate fluid and corrected sodium is progressively rising.

Insulin Strategy in HHS: Withhold insulin at presentation! Fluid resuscitation alone restores renal perfusion, lowering blood glucose by ∼ 5 mmol/L/hour \sim 5\text{ mmol/L/hour} ∼ 5 mmol/L/hour . Start low-dose fixed-rate insulin ( 0.05 units/kg/hour 0.05\text{ units/kg/hour} 0.05 units/kg/hour ) ONLY if blood ketones are ≥ 1.0 mmol/L \ge 1.0\text{ mmol/L} ≥ 1.0 mmol/L or blood glucose ceases to fall with fluid resuscitation alone.

Mandatory Thromboprophylaxis: Extreme hyperviscosity, dehydration, advanced age, and immobility confer a catastrophic risk of arterial and venous thromboembolism. Prophylactic low-molecular-weight heparin (LMWH) is mandatory for all patients unless actively bleeding.

4. DKA vs. HHS: Comparative Analysis

  • Parameter Diabetic Ketoacidosis (DKA) Hyperosmolar Hyperglycaemic State (HHS)
  • Typical Patient Demographics Young Type 1 DM (or SGLT2i-treated T2DM) Elderly Type 2 DM
  • Onset Speed Rapid: hours to < 24 hours < 24\text{ hours} < 24 hours Insidious: days to weeks

Plasma Glucose Typically 14.0 – 30.0 mmol/L 14.0\text{–}30.0\text{ mmol/L} 14.0 – 30.0 mmol/L (or < 11 mmol/L < 11\text{ mmol/L} < 11 mmol/L in euDKA) Typically marked: ≥ 30.0 mmol/L \ge 30.0\text{ mmol/L} ≥ 30.0 mmol/L (often 40 – 80 mmol/L 40\text{–}80\text{ mmol/L} 40 – 80 mmol/L )

Blood Ketones (Beta-hydroxybutyrate) ≥ 3.0 mmol/L \ge 3.0\text{ mmol/L} ≥ 3.0 mmol/L (heavy ketonaemia) < 3.0 mmol/L < 3.0\text{ mmol/L} < 3.0 mmol/L (absent or mild starvation ketosis)

Venous Blood Gas pH < 7.30 < 7.30 < 7.30 (often < 7.10 < 7.10 < 7.10 in severe cases) > 7.30 > 7.30 > 7.30

Venous Bicarbonate < 15.0 mmol/L < 15.0\text{ mmol/L} < 15.0 mmol/L (often < 10 mmol/L < 10\text{ mmol/L} < 10 mmol/L ) > 15.0 mmol/L > 15.0\text{ mmol/L} > 15.0 mmol/L (usually normal)

Anion Gap High ( > 16 mmol/L > 16\text{ mmol/L} > 16 mmol/L ) Normal or mildly elevated

Serum Effective Osmolality Variable (usually < 320 mOsm/kg < 320\text{ mOsm/kg} < 320 mOsm/kg ) Markedly elevated: > 320 mOsm/kg > 320\text{ mOsm/kg} > 320 mOsm/kg

Average Fluid Deficit 5 – 7 litres 5\text{–}7\text{ litres} 5 – 7 litres ( 100 mL/kg 100\text{ mL/kg} 100 mL/kg ) 8 – 12 litres 8\text{–}12\text{ litres} 8 – 12 litres ( 100 – 220 mL/kg 100\text{–}220\text{ mL/kg} 100 – 220 mL/kg )

Primary Resuscitation Goal Clear ketonaemia and correct acidosis Gradual rehydration and slow osmolality reduction

Initial Insulin Administration Immediate fixed-rate infusion ( 0.1 units/kg/h 0.1\text{ units/kg/h} 0.1 units/kg/h ) Withhold initially; start 0.05 units/kg/h 0.05\text{ units/kg/h} 0.05 units/kg/h only if ketonaemia or glucose plateau

Target Rate of Fall Ketones ≥ 0.5 mmol/L/h \ge 0.5\text{ mmol/L/h} ≥ 0.5 mmol/L/h ; glucose ≥ 3.0 mmol/L/h \ge 3.0\text{ mmol/L/h} ≥ 3.0 mmol/L/h Osmolality fall 3.0 – 8.0 mOsm/kg/h 3.0\text{–}8.0\text{ mOsm/kg/h} 3.0 – 8.0 mOsm/kg/h over 48–72h

Major Mortality Drivers Hypokalaemia, cerebral oedema, adult respiratory distress Arterial/venous thromboembolism, hypovolaemic shock, multisystem organ failure

  • 5. Severe Hypoglycaemia & Sulfonylurea Toxicity
  • Clinical Manifestations & Whipple's Triad

Hypoglycaemia is defined clinically by Whipple's Triad :

Symptoms and signs consistent with neuroglycopenia or autonomic activation.

Measured low plasma glucose ( < 4.0 mmol/L < 4.0\text{ mmol/L} < 4.0 mmol/L in diabetic patients; < 3.0 mmol/L < 3.0\text{ mmol/L} < 3.0 mmol/L in healthy individuals).

Prompt resolution of symptoms following carbohydrate administration.

Autonomic Features (threshold ~3.6 mmol/L): Tremor, palpitations, diaphoresis, pallor, anxiety, hunger, perioral paraesthesia.

Neuroglycopenic Features (threshold ~2.8 mmol/L): Confusion, drowsiness, bizarre behaviour, speech difficulty, visual disturbances, seizures, focal neurological deficits (mimicking stroke), coma.

Hypoglycaemia Unawareness: Blunting or loss of sympathetic autonomic warning signs due to repeated episodes of hypoglycaemia inducing central autonomic neuropathy. Markedly increases the risk of severe, catastrophic neuroglycopenia.

Emergency Management Pathways Hypoglycaemia Emergency Algorithm:

- Conscious / Cooperative Patient:

  • → 15–20g fast-acting oral carbohydrate (200 mL fruit juice, 4–5 jelly babies, 170 mL Lucozade)
  • → Recheck capillary glucose at 15 minutes; repeat if < 4.0 mmol/L
  • → Once glucose > 4.0 mmol/L, give long-acting complex carbohydrate (slice of bread, regular meal)

- Impaired Consciousness / Unconscious Patient:

• IV Access Available:

  • → 100–150 mL of 20% Dextrose IV over 10–15 minutes (or 200 mL 10% Dextrose)
  • → Avoid 50% Dextrose (causes severe extravasation injury, chemical phlebitis, rebound hyperinsulinaemia)
  • NO IV Access:
  • → 1 mg Intramuscular (IM) Glucagon (or SC)
  • → Mobilizes hepatic glycogen; ineffective in starvation, liver cirrhosis, or sulfonylurea toxicity
  • Sulfonylurea-Induced Refractory Hypoglycaemia

Sulfonylureas (gliclazide, glimepiride, glibenclamide) bind SUR1 subunits, triggering autonomous insulin exocytosis independent of ambient glucose. Administering boluses of IV dextrose stimulates further endogenous insulin secretion, precipitating vicious cycles of severe rebound hypoglycaemia.

Patients mandate hospital admission and continuous monitoring for at least 24 to 48 hours .

Pharmacological Antidote: If hypoglycaemia recurs despite continuous dextrose infusion, administer octreotide ( 50 – 100 mcg 50\text{–}100\text{ mcg} 50 – 100 mcg SC or IV every 8–12 hours) . Octreotide is a synthetic somatostatin analogue that binds to somatostatin receptor-2 on pancreatic β \beta β -cells, closing voltage-gated calcium channels and shutting down sulfonylurea-stimulated insulin exocytosis.